Pressmeddelande

  • Information in relation to COVID-19

    GOTHENBURG, Sweden, April 2, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has since the…

    by
  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million

    GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that…

    by
  • Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin

    GOTHENBURG, Sweden, March 30, 2020 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that…

    by
  • The first patient included in Japan in Isofol’s Phase 3 AGENT study

    GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by
  • Gene expression analysis method has been validated by a commercial laboratory

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that the method …

    by
  • Over 200 patients now randomized in the Global Phase 3 AGENT Study

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that over 200…

    by
  • The Phase 1/2a study ISO-CC-005 is completed

    GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announces that the recruitment…

    by
  • The first patient included in Australia in Isofol’s Phase 3 AGENT study

    GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by
  • Patent approved in Japan for Isofol’s drug candidate arfolitixorin

    GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL). A patent covering the Active…

    by
  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announces the approval from…

    by